ArticlePloS one2024

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.

Busyamas Chewaskulyong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.